Respiratory failure & ventilation
Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study
Authors' conclusion
Patients with cancer and ARDS, particularly severe forms, experience high 90-day mortality, irrespective of ECMO use.
Study context
- Population
- Patients with cancer and acute respiratory distress syndrome (ARDS) in 13 countries in Europe and North America
- Participants
- 715 patients
- Exposure
- Extracorporeal membrane oxygenation (ECMO) vs no ECMO in severe ARDS
- ECMOn = 58
- Outcome
- Mortality
- Follow-up
- 90 days
Methodological detailsmultinational
- Multinational
Main finding
As reported in the abstract
90-day mortality, all patients
90-day mortality
73.2%
Intensive care unit (ICU) mortality
55.3%
Hospital mortality
70.9%
Observational data: associations, not effects.
Further findings
90-day mortality, severe ARDS at inclusion (subgroup) · unadjusted
P = 0.89
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| 90-day mortality, severe ARDS at inclusion (subgroup) | 1.12 (0.65–1.94) | P = 0.69 | |
| 0.512Adjusted hazard ratio (log scale) |
- 90-day mortality, severe ARDS at inclusion (subgroup) — 90-day mortality, severe ARDS subgroup overall (322 patients, 45.7%)
- 82.2%
- 90-day mortality, severe ARDS at inclusion (subgroup): double-adjusted overlap- and propensity-weighted Cox mixed-effects model
Original publication
Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study. Intensive Care Med. Published 25 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →